Moleculin Biotech (MBRX) said Thursday that certain holders of its existing warrants have agreed to exercise their holdings to purchase about 5.8 million shares of the company at a reduced exercise price of $1 per share.
The company said gross proceeds from the exercise of warrants is expected to total $5.8 million.
In consideration for the exercise of warrants for cash, Moleculin said it will issue new unregistered warrants to buy nearly 11.7 million shares, which will be immediately exercisable at $0.75 per share.
The transaction is expected to close by Friday and net proceeds would be used for working capital and general corporate purposes, the company said.
Price: 2.21, Change: +1.79, Percent Change: +426.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.